Junevity co-founders (L to R): COO Rob Cahill, CSO Janine Sengstack and CEO John Hoekman
February 12, 2025 07:00 AM EST
Financing
R&D

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

Ryan Cross

Senior Science Correspondent

The hu­man genome is chock-full of mid­dle man­agers. Rough­ly 2,000 pro­teins, ac­count­ing for one-tenth of our genes, con­trol how the rest …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Ab­b­Vie pens an­oth­er T cell en­gager deal, this time with Xilio

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

Odyssey un­der­went lay­offs; GSK to move vac­cine R&D site to Cam­bridge

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times